Table 1 Patient demographic und clinical characteristics, n = 71
From: Cough suppression and HRQoL in adult people with cystic fibrosis: an unexplored correlation
All subjects (n = 71) | Male (n = 41) | Female (n = 30) | |
|---|---|---|---|
Age, years | 32.52 ± 11.68 (18–71) | 35.12 ± 12.64* (19–71) | 28.97 ± 9.28 (18–52) |
Sex | 41 (58) | 30 (42) | |
Genotype n, (%) | |||
F508del homozygous | 28 (39) | 12 (29) | 16 (53) |
F508del heterozygous | 31 (44) | 21 (51) | 10 (33) |
Other | 12 (17) | 8 (20) | 4 (13) |
BMI, kg/m2 | 20.27 ± 3.42 (15–33) | 21.22 ± 3,68* (16–33) | 19.97 ± 2.54 (15–25) |
ppFEV1 | 43.17 ± 19.80 (16–99) | 45.95 ± 21,26 (20–99) | 39.37 ± 17.23 (16–82) |
Pancreatic insufficiency n, % | 46 (65) | 22 (54)* | 24 (80) |
CF-related diabetes n, % | 22 (31) | 16 (39) | 6 (20) |
P. aeruginosa positive n, % | 52 (73) | 30 (73) | 22 (73) |
Hospital n, % | |||
Inpatient | 68 (96) | 39 (95) | 29 (97) |
Outpatient | 3 (4) | 2 (5) | 1 (3) |
Reasons for medical treatment n, % | |||
PEX | 34 (48) | 18 (44) | 16 (53) |
Starting CFTR-modulator therapy | 14 (20) | 11(27) | 3 (10) |
IVAT | 8 (11) | 4 (10) | 4 (13) |
Others | 15 (21) | 8 (20) | 7 (23) |
Diagnosis disclosure n, % | |||
Family | 70 (99) | 40 (98) | 30 (100) |
Friends | 49 (70) | 30 (73) | 19 (66) |
Employer | 32 (78) | 20 (83) | 12 (71) |
Colleagues | 15 (37) | 9 (38) | 6 (35) |